Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Efficacy and safety of gadobutrol-enhanced MRA of the renal arteries: Results from GRAMS (Gadobutrol-enhanced renal artery MRA study), a prospective, intraindividual multicenter phase 3 blinded study.

Fabrega-Foster KE, Agarwal S, Rastegar N, Haverstock D, Agris JM, Kamel IR.

J Magn Reson Imaging. 2018 Feb;47(2):572-581. doi: 10.1002/jmri.25774. Epub 2017 Jun 2.

PMID:
28574637
2.

Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies.

Sardanelli F, Newstead GM, Putz B, Jirakova Trnkova Z, Trimboli RM, Abe H, Haverstock D, Rosenberg M.

Invest Radiol. 2016 Jul;51(7):454-61. doi: 10.1097/RLI.0000000000000254.

PMID:
26840494
3.

Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.

Sethi S, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Wilson R.

Infection. 2016 Feb;44(1):65-76. doi: 10.1007/s15010-015-0833-3. Epub 2015 Sep 14.

4.

Correction to "Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study".

Gutierrez JE, Rosenberg M, Seemann J, Breuer J, Haverstock D, Agris J, Balzer T, Anzalone N.

Magn Reson Insights. 2015 Jul 21;8:23. doi: 10.4137/MRI.S30060. eCollection 2015. No abstract available.

5.

Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.

Wilson R, Anzueto A, Miravitlles M, Arvis P, Haverstock D, Trajanovic M, Sethi S.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 2;10:985-93. doi: 10.2147/COPD.S80926. eCollection 2015.

6.

Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study.

Gutierrez JE, Rosenberg M, Seemann J, Breuer J, Haverstock D, Agris J, Balzer T, Anzalone N.

Magn Reson Insights. 2015 Apr 7;8:1-10. doi: 10.4137/MRI.S19794. eCollection 2015. Erratum in: Magn Reson Insights. 2015;8:23.

7.

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.

Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Sethi S.

Eur Respir J. 2012 Jul;40(1):17-27. doi: 10.1183/09031936.00090311. Epub 2011 Dec 1. Erratum in: Eur Respir J. 2012 Sep;40(3):800.

8.

Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis.

Miravitlles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P.

Eur Respir J. 2012 Jun;39(6):1354-60. doi: 10.1183/09031936.00042111. Epub 2011 Oct 27.

9.

A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.

Wilson R, Anzueto A, Miravitlles M, Arvis P, Faragó G, Haverstock D, Trajanovic M, Sethi S.

Int J Chron Obstruct Pulmon Dis. 2011;6:373-83. doi: 10.2147/COPD.S21071. Epub 2011 Jun 29.

10.

Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.

Hadley JA, Mösges R, Desrosiers M, Haverstock D, van Veenhuyzen D, Herman-Gnjidic Z.

Laryngoscope. 2010 May;120(5):1057-62. doi: 10.1002/lary.20878.

PMID:
20422704
11.

Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa.

Saltzstein D, Wachs B, Perroncel R, Benson A, Herrington J, Haverstock D, Pertel P.

J Chemother. 2007 Dec;19(6):694-702.

PMID:
18230553
12.
13.

Risk factors for a poor outcome after therapy for acute pyelonephritis.

Pertel PE, Haverstock D.

BJU Int. 2006 Jul;98(1):141-7.

14.

Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.

Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, Perroncel R.

Respir Med. 2006 Oct;100(10):1781-90. Epub 2006 Mar 13.

15.

Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.

Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J.

Int J Clin Pract. 2005 Nov;59(11):1253-9.

PMID:
16236076
16.
17.

Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.

Hoeffken G, Talan D, Larsen LS, Peloquin S, Choudhri SH, Haverstock D, Jackson P, Church D.

Eur J Clin Microbiol Infect Dis. 2004 Oct;23(10):772-5.

PMID:
15605184
18.

Clinical experience with moxifloxacin in patients with respiratory tract infections.

Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalsky SF, Haverstock DC, Celesk RA, Church DA.

Ann Pharmacother. 2004 May;38(5):749-54. Epub 2004 Mar 16.

PMID:
15026565
19.

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.

Lode H, Grossman C, Choudhri S, Haverstock D, McGivern J, Herman-Gnjidic Z, Church D.

Respir Med. 2003 Oct;97(10):1134-42.

20.

Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.

Henry DC Jr, Bettis RB, Riffer E, Haverstock DC, Kowalsky SF, Manning K, Hamed KA, Church DA.

Clin Ther. 2002 Dec;24(12):2088-104.

PMID:
12581547
21.

Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.

Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR.

Ann Intern Med. 2002 Jul 16;137(2):77-87.

PMID:
12118962
22.

Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection.

Gomolin IH, Siami PF, Reuning-Scherer J, Haverstock DC, Heyd A; Oral Suspension Study Group.

J Am Geriatr Soc. 2001 Dec;49(12):1606-13.

PMID:
11843992
23.

Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections.

Parish LC, Routh HB, Miskin B, Fidelholtz J, Werschler P, Heyd A, Haverstock D, Church D.

Int J Clin Pract. 2000 Oct;54(8):497-503.

PMID:
11198726
24.
25.

Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.

Cohn SM, Lipsett PA, Buchman TG, Cheadle WG, Milsom JW, O'Marro S, Yellin AE, Jungerwirth S, Rochefort EV, Haverstock DC, Kowalsky SF.

Ann Surg. 2000 Aug;232(2):254-62.

26.
28.

Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group.

Burke T, Villanueva C, Mariano H Jr, Huck W, Orchard D, Haverstock D, Heyd A, Church D.

Clin Ther. 1999 Oct;21(10):1664-77.

PMID:
10566563
29.

Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation.

Kanga J, Kuhn R, Craigmyle L, Haverstock D, Church D.

Clin Ther. 1999 Aug;21(8):1343-56.

PMID:
10485506
30.

Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis.

Echols RM, Tosiello RL, Haverstock DC, Tice AD.

Clin Infect Dis. 1999 Jul;29(1):113-9.

PMID:
10433573
31.

Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.

Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, Echols R.

J Antimicrob Chemother. 1999 Mar;43 Suppl A:117-28.

PMID:
10225582
32.

Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review.

Segev S, Yaniv I, Haverstock D, Reinhart H.

Clin Infect Dis. 1999 Feb;28(2):299-308.

PMID:
10064248
34.
35.

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.

Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, Painter BG, Thurberg BE, Haverstock DC, Perroncel RY, Echols RM.

Pediatr Infect Dis J. 1997 Jan;16(1):97-105; discussion 123-6.

PMID:
9002118
36.

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.

Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, Simms HH, Hill CS, Bjornson HS, Haverstock DC, Coulter HO, Echols RM.

Ann Surg. 1996 Mar;223(3):303-15.

37.

Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.

Burnett RJ, Haverstock DC, Dellinger EP, Reinhart HH, Bohnen JM, Rotstein OD, Vogel SB, Solomkin JS.

Surgery. 1995 Oct;118(4):716-21; discussion 721-3.

PMID:
7570327
38.

Good looking & good-for-you food.

Haverstock D.

Restaurants Inst. 1989 Dec 11;99(32):126-7, 130, 134 passim. No abstract available.

PMID:
10296487

Supplemental Content

Loading ...
Support Center